Lineage Cell Therapeutics (LCTX) Receivables - Net (2011 - 2026)

Lineage Cell Therapeutics' Receivables - Net history runs 16 years deep, the most recent figure standing at $806000.0 for Q1 2026.

• On a quarterly basis, Receivables - Net rose 278.4% year-over-year to $806000.0 in Q1 2026; TTM through Mar 2026 was $806000.0, a 278.4% increase from a year earlier, with the FY2025 full-year figure at $891000.0, up 39.66% from the prior year.
• Receivables - Net slipped to $806000.0 in Q1 2026 per LCTX's latest filing, from $891000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $891000.0 in Q4 2025 and bottomed at $77000.0 in Q1 2024.
• The 5-year median for Receivables - Net is $405000.0 (2024), against an average of $411411.8.
• Across the five-year window, Receivables - Net plunged 99.41% in 2022 and surged 278.4% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $300000.0 in 2022, then jumped by 148.33% to $745000.0 in 2023, then decreased by 14.36% to $638000.0 in 2024, then jumped by 39.66% to $891000.0 in 2025, then fell by 9.54% to $806000.0 in 2026.
• Per Business Quant, the three latest LCTX Receivables - Net figures stand at $806000.0 (Q1 2026), $891000.0 (Q4 2025), and $127000.0 (Q3 2025).